DateOctober 31, 2016
Updated - October 2016: FHI 360 renews its commitment to expand the evidence base for family planning programming and the translation of evidence into policy and practice. In response to a lack of knowledge about the association between hormonal contraception and HIV acquisition, FHI 360 will provide evidence to support contraceptive decision-making for women at risk of HIV infection who also wish to avoid pregnancy. FHI 360 continues its commitment to make family planning more accessible through task-shifting, by conducting research and advocacy for policy change. FHI 360 will continue to work with government stakeholders in FP2020 countries to develop, implement, and monitor costed implementation plans for family planning. In addition, FHI 360 will advocate for the inclusion of family planning as an essential part of an integrated approach to development; when women and girls are able to plan the size of their families and time their pregnancies, we make progress on nearly every Sustainable Development Goal.
July 11, 2012: FHI 360 will expand the evidence base for safe and effective family planning and will translate high-quality evidence into policy and practice.
DateOctober 31, 2016
Updated - October 2016: FHI 360 commits to progressing at least 5 new contraceptive methods through the development pipeline. FHI 360 also pledges to support the introduction of new and affordable IUDs into FP2020 target countries. Development and introduction of new contraceptive technologies, particularly long-acting methods, will not only help meet the goals of FP2020, but also maintain and expand those successes in the coming decades.
July 11, 2012: FHI 360 plans to continue its efforts to widen the array of safe, effective, acceptable and affordable contraceptives worldwide.
DateSeptember 28, 2014
The Population Council will promote reproductive rights to reduce inequalities in access to and use of reproductive health services related to wealth, age and gender; strengthen health systems so that contraception can be provided through a range of health services; develop and test the effectiveness, safety and acceptability of new reproductive health technologies designed to benefit women and men in developing countries; and engage pharmaceutical companies to license, register and/or manufacture technologies developed by the Population Council to expand choice in developing country markets.
The Population Council provided the following updates on progress in achieving its FP2020 commitments:
The Council is examining how service delivery options outside of the formal health systems, such as pharmacies and drug shops, and workplace settings, can play an increased role in the provision of an expanded range of contraceptive methods. Expanding the range of contraceptive products available in markets not only increases uptake but simultaneously influences the supply side of service delivery as additional methods offered by providers serves to strengthen the supply chain and health system.
Developing and testing the effectiveness, safety and acceptability of new reproductive health technologies designed to benefit women and men in developing countries: The Population Council, with support from the USAID Office of Population and Reproductive Health, has developed two innovative contraceptive vaginal rings: a one-year contraceptive vaginal ring that can be used by women to plan their pregnancies and a three-month vaginal ring that can be used by breastfeeding women. Long-acting vaginal rings represent an important advance in contraceptive development. These methods are especially beneficial for women in low-resource settings since they are designed to be under the woman’s control and do not require insertion by a healthcare provider or regular visits to a pharmacy. Both of these factors stand to dramatically expand access to family planning options.
Engaging pharmaceutical companies to license, register and/or manufacture technologies developed by the Population Council to expand choice in developing country markets: In 2014, Population Council researchers completed studies required for the registration and introduction of the progesterone CVR in counties in Kenya, Nigeria, and Senegal. In India, the Council and the Indian Council of Medical Research evaluated the safety and efficacy of the progesterone CVR compared to the Copper T IUD in breastfeeding women who wish to space their pregnancies.
Additionally, the International Contraceptive Access (ICA) Foundation is a priority initiative for the Council. The ICA Foundation, a public–private partnership between the Council and Bayer OY, is helping expand access to long-acting reversible contraception in low-resource settings. The objective of the Foundation is to provide local service-delivery organizations with the levonorgestrel releasing intrauterine system (LNG IUS) contraceptive devices on a not-for-profit basis and ultimately serve the reproductive needs of women in resource-poor settings, primarily in developing countries. To date, the Foundation has provided over 67,000 LNG IUS and training materials to projects in 28 low- and middle-income countries. Since 2012 alone, the foundation has donated more than 19,000 units of LNG IUS and related education materials. Country projects include collaborations with local not-for-profit organizations, hospitals, and global partners with a network of service delivery facilities in developing countries.
DateOctober 31, 2012
Updated - October 2016: FHI 360 increases its financial commitment, from an original pledge of US$1 million of its own resources to a renewed pledge of US$3 million. These funds will be spent to support the development and introduction of new contraceptive technologies that will provide women in the developing world with additional high-quality, low-cost family planning options. As of the FP2020 mid-point, FHI 360 had contributed US$2.29 million of its own resources.
July 11, 2012: FHI 360 commits to allocating US $1 million of their resources through 2020 in support of the development and introduction of new contraceptive technologies that will provide women in the developing world with additional high-quality, low-cost family planning options to fill gaps and expand choice.
DateJuly 11, 2012
The foundation will also support research and development to create new contraceptives that can better serve the needs and circumstances of more women in the poorest countries around the world.
In August 2015, the Bill & Melinda Gates Foundation shared an update on progress in achieving its commitments to FP2020.
By cultivating high-level political leadership around countries’ FP2020 commitments, the Gates Foundation and its grantees have been able to work with government to expand access to family planning in priority countries. For example:
DateJuly 11, 2012
The Aman Foundation’s funds will help facilitate research in integrated family health service delivery and family planning programs that help increase the number of new family planning users through improved quality of services, introduction to new contraceptive methods, innovative service-delivery interventions, and demand generation. The Aman Foundation also commits to enhancing partnerships with local community-based organizations, the private sector, and the public sector through an integrated community-based approach. The Aman Foundation will improve quality and effectiveness of family planning programs and services in the targeted project areas and will help to increase women's and girls’ ability to make informed decisions and have access to the most appropriate family planning services and supplies.